Neurocrine biosciences to present new ingrezza® (valbenazine) and ongentys® (opicapone) data at the mds virtual congress 2021

San diego, sept. 10, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (td) and parkinson's disease at the international parkinson and movement disorder society's (mds) virtual congress 2021 being held september 17–22, 2021.
NBIX Ratings Summary
NBIX Quant Ranking